These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 24659608)
1. Development of therapeutic polymeric nanoparticles for the resolution of inflammation. Gadde S; Even-Or O; Kamaly N; Hasija A; Gagnon PG; Adusumilli KH; Erakovic A; Pal AK; Zhang XQ; Kolishetti N; Shi J; Fisher EA; Farokhzad OC Adv Healthc Mater; 2014 Sep; 3(9):1448-1456. PubMed ID: 24659608 [TBL] [Abstract][Full Text] [Related]
2. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796 [TBL] [Abstract][Full Text] [Related]
3. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752 [TBL] [Abstract][Full Text] [Related]
4. Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells. Nunomura S; Okayama Y; Matsumoto K; Hashimoto N; Endo-Umeda K; Terui T; Makishima M; Ra C Allergol Int; 2015 Sep; 64 Suppl():S11-7. PubMed ID: 26344074 [TBL] [Abstract][Full Text] [Related]
5. Characterization of Redox-Responsive LXR-Activating Nanoparticle Formulations in Primary Mouse Macrophages. Smith TKT; Kahiel Z; LeBlond ND; Ghorbani P; Farah E; Al-Awosi R; Cote M; Gadde S; Fullerton MD Molecules; 2019 Oct; 24(20):. PubMed ID: 31635211 [TBL] [Abstract][Full Text] [Related]
6. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα. Kiss E; Popovic Z; Bedke J; Wang S; Bonrouhi M; Gretz N; Stettner P; Teupser D; Thiery J; Porubsky S; Adams J; Gröne HJ Am J Pathol; 2011 Jul; 179(1):92-103. PubMed ID: 21703396 [TBL] [Abstract][Full Text] [Related]
7. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Morales JR; Ballesteros I; Deniz JM; Hurtado O; Vivancos J; Nombela F; Lizasoain I; Castrillo A; Moro MA Circulation; 2008 Sep; 118(14):1450-9. PubMed ID: 18794391 [TBL] [Abstract][Full Text] [Related]
8. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Laffitte BA; Joseph SB; Chen M; Castrillo A; Repa J; Wilpitz D; Mangelsdorf D; Tontonoz P Mol Cell Biol; 2003 Mar; 23(6):2182-91. PubMed ID: 12612088 [TBL] [Abstract][Full Text] [Related]
9. LXR as a novel antithrombotic target. Spyridon M; Moraes LA; Jones CI; Sage T; Sasikumar P; Bucci G; Gibbins JM Blood; 2011 May; 117(21):5751-61. PubMed ID: 21411760 [TBL] [Abstract][Full Text] [Related]
10. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Yasuda T; Grillot D; Billheimer JT; Briand F; Delerive P; Huet S; Rader DJ Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):781-6. PubMed ID: 20110577 [TBL] [Abstract][Full Text] [Related]
11. Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. Park MC; Kwon YJ; Chung SJ; Park YB; Lee SK Rheumatology (Oxford); 2010 May; 49(5):882-90. PubMed ID: 20159908 [TBL] [Abstract][Full Text] [Related]
12. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Kamaly N; Fredman G; Subramanian M; Gadde S; Pesic A; Cheung L; Fayad ZA; Langer R; Tabas I; Farokhzad OC Proc Natl Acad Sci U S A; 2013 Apr; 110(16):6506-11. PubMed ID: 23533277 [TBL] [Abstract][Full Text] [Related]
13. The role of the liver X receptor in chronic obstructive pulmonary disease. Higham A; Lea S; Plumb J; Maschera B; Simpson K; Ray D; Singh D Respir Res; 2013 Oct; 14(1):106. PubMed ID: 24118845 [TBL] [Abstract][Full Text] [Related]
14. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. Miao B; Zondlo S; Gibbs S; Cromley D; Hosagrahara VP; Kirchgessner TG; Billheimer J; Mukherjee R J Lipid Res; 2004 Aug; 45(8):1410-7. PubMed ID: 15145986 [TBL] [Abstract][Full Text] [Related]
15. Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury. Lei P; Baysa A; Nebb HI; Valen G; Skomedal T; Osnes JB; Yang Z; Haugen F Basic Res Cardiol; 2013 Jan; 108(1):323. PubMed ID: 23266787 [TBL] [Abstract][Full Text] [Related]
16. Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice. Archer A; Venteclef N; Mode A; Pedrelli M; Gabbi C; Clément K; Parini P; Gustafsson JÅ; Korach-André M Mol Endocrinol; 2012 Dec; 26(12):1980-90. PubMed ID: 23073827 [TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target. Hong C; Walczak R; Dhamko H; Bradley MN; Marathe C; Boyadjian R; Salazar JV; Tontonoz P J Lipid Res; 2011 Mar; 52(3):531-9. PubMed ID: 21187453 [TBL] [Abstract][Full Text] [Related]
18. Reciprocal negative cross-talk between liver X receptors (LXRs) and STAT1: effects on IFN-γ-induced inflammatory responses and LXR-dependent gene expression. Pascual-García M; Rué L; León T; Julve J; Carbó JM; Matalonga J; Auer H; Celada A; Escolà-Gil JC; Steffensen KR; Pérez-Navarro E; Valledor AF J Immunol; 2013 Jun; 190(12):6520-32. PubMed ID: 23686490 [TBL] [Abstract][Full Text] [Related]
19. Activation of liver X receptor attenuates endothelin-1 expression in vascular endothelial cells. Gao M; Zeng Y; Guan Y; Hu Z; Zhong D; Shen X; Zhang L; Xu Z; Gong W; Zhang Y; Zhang M; Zheng Y; He F Int J Biochem Cell Biol; 2012 Dec; 44(12):2299-307. PubMed ID: 23018104 [TBL] [Abstract][Full Text] [Related]
20. Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism. Nguyen-Vu T; Vedin LL; Liu K; Jonsson P; Lin JZ; Candelaria NR; Candelaria LP; Addanki S; Williams C; Gustafsson JÅ; Steffensen KR; Lin CY Breast Cancer Res; 2013 Jun; 15(3):R51. PubMed ID: 23809258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]